Literature DB >> 76519

The alpha2-plasmin inhibitor levels in liver diseases.

N Aoki, T Yamanaka.   

Abstract

Concentrations of alpha-2 plasmin inhibitor, which is a primary and fast-reacting inhibitor of plasmin, were measured immunochemically in sera of patients with liver diseases and compared with normal controls. Serum level of alpha2-plasmin inhibitor was significantly decreased in liver cirrhosis and other severely affected liver diseases. The decrease appeared to be dependent upon the extent of liver damage, and the level of alpha2-plasmin inhibitor was closely correlated with parameters of liver functions of protein synthesis such as albumin concentration and cholinesterase activity in serum. The level of alpha2-plasmin inhibitor was fairly well correlated with the fibrinolysis inhibitor activity of serum. In contrast to alpha2-plasmin inhibitor, levels of alpha2-macroglobulin and alpha1-antitrypsin were increased significantly in liver cirrhosis. It was suggested that the reduction of alpha2-plasmin inhibitor level contributes substantially to the increased fibrinolytic activity observed in liver cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 76519     DOI: 10.1016/0009-8981(78)90481-3

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  15 in total

1.  Hyperfibrinolysis in hepatosplenic schistosomiasis.

Authors:  N E el-Bassiouni; A E el Bassiouny; H R el-Khayat; M M Akl; S A Omran
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.

Authors:  N A Booth; J A Anderson; B Bennett
Journal:  J Clin Pathol       Date:  1984-07       Impact factor: 3.411

3.  Profiles of acute-phase reactants and clinical significance of alpha 2-macroglobulin in acute hepatitis B.

Authors:  J Van Gool
Journal:  Inflammation       Date:  1983-09       Impact factor: 4.092

4.  Synthesis and secretion of alpha 2-plasmin inhibitor by established human liver cell lines.

Authors:  H Saito; L T Goodnough; B B Knowles; D P Aden
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

5.  Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1982-03       Impact factor: 14.808

6.  Usefulness of antithrombin III and alpha 2-plasmin inhibitor in early differentiation of fulminant hepatitis and severe form of acute hepatitis.

Authors:  S Sato; A Murakami; T Yoshida; T Kashiwabara; K Suzuki; I Kaito
Journal:  Gastroenterol Jpn       Date:  1983-04

7.  Congenital deficiency of alpha 2-plasmin inhibitor associated with severe hemorrhagic tendency.

Authors:  N Aoki; H Saito; T Kamiya; K Koie; Y Sakata; M Kobakura
Journal:  J Clin Invest       Date:  1979-05       Impact factor: 14.808

8.  Cross-linking of alpha 2-plasmin inhibitor to fibrin by fibrin-stabilizing factor.

Authors:  Y Sakata; N Aoki
Journal:  J Clin Invest       Date:  1980-02       Impact factor: 14.808

9.  Epsilon-aminocaproic acid for treatment of fibrinolysis during liver transplantation.

Authors:  Y Kang; J H Lewis; A Navalgund; M W Russell; F A Bontempo; L S Niren; T E Starzl
Journal:  Anesthesiology       Date:  1987-06       Impact factor: 7.892

10.  Extravascular plasminogen activator and inhibitor activities detected at the site of a chronic mycobacterial-induced inflammation.

Authors:  J O'Rourke; W P Wang; L Donnelly; E Wang; D L Kreutzer
Journal:  Am J Pathol       Date:  1987-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.